Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in anti-CCP positive undifferentiated arthritis
ACTRN12605000785606Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2006
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in undifferentiated arthritis (UA) comparing Abatacept with Placebo (2 arms). Started Jan 2006; status: active, not recruiting.
02
Drugs
abatacept
03
Conditions
undifferentiated arthritis (UA)
Beyond the preview
Go deeper on ACTRN12605000785606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000785606.